18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevaclzumab-based therapy

Chiara Funaioli, Carmine Pinto, Francesca Di Fabio, Donatella Santini, Claudio Ceccarelli, Emilio De Raffaele, Stefano Fanti, Paolo Castellucci, Ciro Longobardi, Federico Buggi, Andrea Angelo Martoni

Research output: Contribution to journalArticle

Abstract

Around 20-30% of patients with hepatic metastasis from colorectal cancer can undergo liver resection, but the increased response rate obtained with the addition of monoclonal antibodies to chemotherapy regimens could result in a higher rate of liver surgery. In this report we describe the case of a patient who underwent a liver resection after neoadjuvant treatment with capecitabine, oxaliplatin and bevacizumab and who achieved a complete pathological response of the liver metastasis. A preoperative CT scan demonstrated a partial response to the treatment while 18FDG-PET scan correctly evaluated the complete pathological response in the liver and detected an active interaortocaval lymph node metastasis. New specific studies are required to evaluate the imaging response in metastatic colorectal cancer patients especially after treatment with new, targeted agents.

Original languageEnglish
Pages (from-to)611-615
Number of pages5
JournalTumori
Volume93
Issue number6
Publication statusPublished - Nov 2007

    Fingerprint

Keywords

  • Bevacizumab
  • Colorectal cancer
  • Liver metastases
  • PET

ASJC Scopus subject areas

  • Cancer Research

Cite this

Funaioli, C., Pinto, C., Di Fabio, F., Santini, D., Ceccarelli, C., De Raffaele, E., Fanti, S., Castellucci, P., Longobardi, C., Buggi, F., & Martoni, A. A. (2007). 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevaclzumab-based therapy. Tumori, 93(6), 611-615.